Medlab Clinical Limited (MDC:ASX)


right-arrow Created with Sketch. 0 (0%)
MCAP $90.89M
Last trade 14.57pm 03/03/2021 20mins delayed

Latest Announcements

24/02/2021MDCMedlab Clinical Limited
24/02/2021 Price SensitivePSMDCMedlab Clinical Limited
18/02/2021 Price SensitivePSMDCMedlab Clinical Limited
11/02/2021 Price SensitivePSMDCMedlab Clinical Limited
25/01/2021 Price SensitivePSMDCMedlab Clinical Limited
20/01/2021MDCMedlab Clinical Limited
19/01/2021MDCMedlab Clinical Limited
19/01/2021 Price SensitivePSMDCMedlab Clinical Limited

Company Overview

Medlab Clinical Limited is engaged in the sale of nutraceutical products and pharmaceutical research. The Company operates through two segments: Nutraceutical and Pharmaceutical Research. Its Manuka-C is scientifically formulated to support optimal immune system function and includes evidence-based ingredients containing a blend of over three ascorbates combined with glutathione and Manuka honey powder. Its NOS NITRIC OXIDE SUPPORT is a pre-exercise sports food containing a selection of evidence-based ingredients combined to support and optimize exercise performance. Its Saccharomyces cerevisiae ssp. boulardii (SB) 5B is a probiotic yeast that helps to maintain gastrointestinal function and integrity by supporting a healthy gut microbial profile; by increasing the production of secretory Immunoglobulin A (sIgA), short-chain fatty acids (SCFAs) and helping to promote the activity of brush border disaccharide enzymes. It also offers Mg Optima and BioClean EPA:DHA + CoQ10.

MDC in the news

Search Previous Announcements